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1. Introduction
Uric acid is a weak acid distributed throughout the extracellular fluid compartments
(Emmerson, 1996). The normal blood uric acid level in humans is approximately 4 mg/dl (0.24
mmol/l) (Ganong, 2005). Uric acid is the end product of purine degradation. Purines are
degraded ultimately to uric acid through the action of the enzyme xanthine oxidase that
converts xanthine to urate (Mc Lean, 2003). In most mammals, the liver enzyme uricase (urate
oxidase) is responsible for further metabolism of uric acid to allantoin, which is more soluble
waste product. However, humans lack the enzyme uricase, resulting in higher blood uric acid
levels (Hediger et al., 2005). They might provide humans a survival advantage over the other
primates because of the function of uric acid as antioxidant (Mc Lean, 2003). ). For an individ‐
ual, urate concentration is determined by the balance between the rate of purine metaboloism,
both endogenous and exogenous, and the efficiency of renal clearance. Alteration in this
balance may account for hyperuricemia. In the majority (90%) of patients with primary gout,
hyperuricemia results from relative renal undersecretion, whereas in 10% of patients, there is
overproduction of endogenous uric acid (Fam, 2002).
Elevated serum uric acid, besides its documented link to gouty arthritis, has been reported to
be closely-associated with the metabolic syndrome and, as well, to be a correlate of the
development and progression of cardiovascular diseases (Baker et al., 2005), though the role
of uric acid in this respect is still unclear. Several possible pathological mechanisms linking
hyperuricemia to cardiovascular disease were suggested; including the deleterious effects of
elevated uric acid on endothelial dysfunction, oxidative metabolism, as well as platelet
adhesiveness, hemorheology and aggregation (Hoieggen et al., 2003). However, no enough or
definite experimental data exist concerning the association of hyperuricemia with the different
cellular elements of blood. The aim of this work was to investigate the effects of elevated serum
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uric acid levels on the physiology of the different cellular blood elements in rats and their link
to cardiovascular ailment.
2. Methods
This study was performed on 58 albino rats, of both sexes, weighing 180- 250g. Rats included
in the present study were divided into 2 main groups: hyperuricemic group (group I) and
normouricemic control group (group II). Hyperuricemia was achieved by using the uricase
inhibitor oxonic acid (oxonic acid, potassium salt, supplied by Acros Organics, Geel, Belgium),
with concomitant supplementation of diet with 3% uric acid. Oxonic acid was administered
orally for 5 days, 2 and 4 weeks by gavage in a dose of 750 mg/kg body weight (Khosla et al.,
2005), dissolved in 0.25% methylcellulose. Concomitant supplementation of diet with uric acid
was done to obtain better and maintained hyperuricemic response (Mazzali et al., 2001). The
control groups were received the solvent orally for 5 days, 2 and 4 weeks. Studied rats were
allocated into the following groups and subgroups: Group I: Hyperuricemic rats, that received
the oxonic/uric acid regimen. Rats in this group were further subdivided into 3 subgroups
according to the duration of hyperuricemia: Group Ia: Five-days hyperuricemic rats (n=10),
receiving the oxonic/uric acid regimen for 5 consecutive days. Group Ib: Two-weeks hyper‐
uricemic rats (n=11), receiving the regimen 6 days/week for 2 weeks. Group Ic: Four-weeks
hyperuricemic rats (n=10), receiving the regimen 6 days /week for 4 weeks. Group II: Nor‐
mouricemic control rats, that received methylcellulose, the solvent for oxonic acid, orally by
gavage. Rats in this group were further subdivided into 3 subgroups, matching the hyperur‐
icemic subgroups:
Group IIa: Five-days control rats (n=8), receiving the solvent for five consecutive days. Group
IIb: Two-weeks control rats (n=8), receiving the solvent 6 days/week for 2 weeks. Group IIc:
Four-weeks control rats (n=11), receiving the solvent 6 days/week for 4 weeks.
Experimental procedure: At the end of the experimental period, overnight fasted rats were
weighed and anaesthetized with intraperitoneal injection of sodium thiopental (40 mg/kg body
weight). One ml of blood was drawn into a tube containing EDTA for assessment of complete
blood picture. Three ml of blood was collected in a chilled plastic tube containing sodium
citrate 3.8%, gently mixed for assessment of platelet aggregation. Another blood samples were
collected in chilled plastic tubes containing sodium citrate 3.8gm/100 ml (9 volumes of blood
to 1 volume of sodium citrate) and gently shaken. These blood samples were used for study
of platelet aggregation. The citrated blood was centrifuged at 1500 r.p.m. for 5 min. The
supernatant platelet rich plasma (PRP) was pipetted into clean plastic tubes. The remaining
blood sample was centrifuged at 10,000 r.p.m. for 10 min. to prepare platelet poor plasma
(PPP). Standard PRP: the number of platelets in PRP was counted using coulter T-660 counter.
The platelet number was adjusted to a standardized number of 3 x 105 platelet per μl by dilution
with autologus platelet poor plasma.
Aggregation study: platelet aggregation was performed using Chrono-Log automatic aggreg‐
ometer (model 540-VC, Chrono-Log Corp, Harvertown, USA) coupled with computer and
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printer. ADP as an aggregating agent was used at a final concentration of 10 uM. The maximum
aggregation was recorded after 3 min. Platelet aggregation was tested by the turbidimetric
technique, according to the method of Mustard et al. (1964). Platelet aggregation was induced
in stirred platelet-rich plasma (PRP) by addition of the aggregating agent ADP (Park com).
The platelet count in PRP was adjusted to a standardized number of 3x105 platelet/μl by
dilution with autologus platelet poor plasma to obtain standard PRP. Platelet aggregation was
performed by the use of a chrono-Log automatic aggregometer (model 540, chrono-Log
Corporation, Harvertown, USA), coupled with computer and printer.
Enzymatic determination of plasma uric acid was carried out according to the method of
Barhan and Trinder (1972). Nitrate concentration in plasma was estimated according to the
method described by Bories and Bories (1995). C-reactive protein (CRP) was determined
qualitatively by the use of latex slide test, described by Singer et al. (1957).
3. Results
Administration of oxonic/uric acid regimen for 5 days, 2 and 4 weeks resulted in a highly
significant hyperuricemic response, being less marked in the 4-weeks treated group. This
observation could be explained by increased urinary uric acid excretion in the later group.
Hediger et al. (2005) demonstrated increased mRNA transcription of the urate transporters
(URAT1) in association with hyperuricemia. No significant changes were found as regard
erythrocyte parameters, platelet count or mean platelet volume between hyperuricemic and
control groups.
As regards the leucocyte changes accompanying hyperuricemia, the neutrophil% was
significantly increased and lymphocyte % was significantly decreased compared to control
values despite the non-significant changes in the total leucocytic count. Neutrophils were
speculated to liberate a potent activation signal after interaction with monosodium urate
crystals, and that this activation can further stimulate surrounding neutrophils and contribute
to amplification of the inflammatory response, with the redox pathways being implicated in
these reactions (Desaulniers et al., 2006). Further, C-reactive protein, the systemic inflamma‐
tory marker, was markedly increased in the 2- and 4-weeks hyperuricemic rats compared to
controls. Uric acid was reported to induce expression of CRP in vascular endothelial and
smooth muscle cells, which was proposed to provide a pathogenic link to explain the associ‐
ation of the systemic inflammatory response and elevated uric acid in patients with cardio‐
vascular disease and diabetes.(Kang et al., 2005; Saito et al., 2003). The increased neutrophil %,
and the significant positive correlation observed between uric acid level and neutrophil %,
together with the increased CRP, encountered in the present study, support the previous
findings of Ruggiero et al.(2006) pointing to significant and independent association of uric
acid level with neutrophil count and CRP level. On the other hand, the lymphocyte % was
significantly reduced in all the hyperuricemic groups. The encountered lymphocytopenia
could be attributed to the increased free radical burden in hyperuricemia, leading to increased
lymphocyte apoptosis. Uric acid has been demonstrated to act in some instances as prooxidant,
generating free radicals (Patterson et al., 2003).
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Figure  1.  changes  in  plasma uric  acid  in  the  different  hyperuricemic  groups  
 
 and their  matching control
groups 
 
With regard to platelet changes associated with hyperuricemia, enhanced ADP-induced pla‐
telet aggregation was encountered in all the hyperuricemic groups compared to controls, the
effect being more marked in the 5-days and 2-weeks groups, showing higher uric acid lev‐
els. Moreover, a significant positive correlation between plasma uric acid and platelet aggre‐
gation was demonstrated in all the tested groups of rats. The observed enhancement of
platelet aggregation is in accordance with previous reports (Alderman and Aiyer, 2004).
The enhanced platelet aggregation demonstrated in the present study could be explained by
many mechanisms. Urate crystals were reported to stimulate arachidonic acid metabolism in
platelets.(Serhan et al., 1984) Moreover, neutrophilia demonstrated in the present study might
contribute to platelet hyperaggregability, as neutrophils were reported to be potent inducers
of platelet Ca2+ flux, aggregation and secretion. (Faint, 1992). Furthermore, the observed
lymphocytopenia could play a role in the increased platelet activity. In 1987, Wu et al. proposed
lymphocytes to possess PGI2 synthase activity which is capable of converting platelet-derived
PGH2 into PGI2 that is sufficient to inhibit platelet function. Therefore, the encountered
decrease in lymphocytes could provide an additional explanation for the enhanced platelet
aggregability.
The observed decrease in plasma nitrate level in the 4-weeks hyperuricemic rats, together with
the significant negative correlation between plasma levels of uric acid and nitrate demonstrat‐
ed in this group, reflect possible lowering of nitric oxide (NO) bioavailability with prolongation
of hyperuricemia. Reduced NO production in association with hyperuricemia has been
reported by several investigators.(Waring and Esmail, 2005) The reduced NO, together with
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the inflammatory response, could imply increased risk of cardiovascular pathology in
hyperuricemic subjects by promoting development of endothelial dysfunction.
In conclusion, the neutrophil and platelet activation, known predisposing factors to throm‐
bosis, together with increased CRP production and reduced NO production, might share in
causing the hyperuricemia-associated endothelial dysfunction and atherosclerotic plaque
formation. Therefore, it could be recommended that physicians should be aware of the role of
elevated uric acid in inducing cardiovascular insult, and that individuals suffering from
hyperuricemia should be advised to have a strict follow-up for their platelet function, which
could participate in the cardiovascular pathology.
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Figure 2. changes in plasma nitrate in the normouricemic 
 
 and the different hyperuricemic groups 
 
Duration
Parameter
5-days hyperuricemia 2-weeks hyperuricemia 4-weeks hyperuricemia
Control
rats
Hyper-
uricemic rats
P
Control
rats
Hyper-
uricemic rats
P
Control
rats
Hyper-
uricemic rats
P
TLC
(x103/µl)
3.2±0.38
(7)
3.0±0.56
(9)
NS
2.8±0.39
(7)
3.2±0.59
(9)
NS
3.7±0.52
(9)
3.9±0.76
( 10 )
NS
Neutrophil (%)
31.6±2.93
( 7 )
53.1±3.87
( 9 )
<0.001
34.4±4.25
( 7 )
56.9±6.92
(9)
<0.0
5
35.0±7.25
(9)
58±6.42
(10)
<0.0
5
Lymphocyte %
67.6±3.37
( 7 )
46.2±4.00
( 9 )
<0.01
64.3±4.12
( 7 )
41.0±7.17
( 9 )
<0.0
5
64.6±7.23
( 9 )
41.5±6.33
( 10)
<0.0
5
Table 1. Results of the changes in leucocyte parameters in the different studied groups P: Significance of difference
from matched control rats calculated by Student’s ″t″test for unpaired data. NS: Not significant.
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Figure 3. Tracing of ADP-induced platelet aggregation in the different studied groups; 5 days normouricemic rats (A),
hyperuricemic rats for 5 days (B), normouricemic rats for 2 weeks (C), hyperuricemic rats for 2 weeks (D), normourice‐
mic rats for 4 weeks (E) and hyperuricemic rats for 4 weeks (F).
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Figure 4. Graphs showing correlations of plasma uric acid versus neutrophil %, lymphocyte%, and platelet aggrega‐
tion in all the studied groups of rats.
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